Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Roberto Visentin"'
Autor:
Roberto Visentin, Katrine Brodersen, Bjørn Richelsen, Niels Møller, Chiara Dalla Man, Andreas Kristian Pedersen, Jan Abrahamsen, Jens Juul Holst, Michael Festersen Nielsen
Publikováno v:
Journal of Diabetes Research, Vol 2023 (2023)
Background. β-cell dysfunction and insulin resistance are the main mechanisms causing glucose intolerance in type 2 diabetes (T2D). Bariatric surgeries, i.e., sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), are procedures both known to
Externí odkaz:
https://doaj.org/article/9cb47ce89a91450ea932181b19c85fdf
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/3aaddb39af0d4926ae1aed2ec20cefe7
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187754 (2017)
The large patient variability in human physiology and the effects of variables such as exercise or meals challenge current prediction modeling techniques. Physiological models are very precise but they are typically complex and specific physiological
Externí odkaz:
https://doaj.org/article/74fb7731e9ef4666878608df2584b792
Autor:
Chiara Dalla Man, Michela Riz, Roberto Visentin, Claudio Cobelli, Thomas Klabunde, Michele Schiavon, Britta Göbel
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To gain further insights into the efficacy of SAR425899, a dual glucagon‐like peptide‐1/glucagon receptor agonist, by providing direct comparison with the glucagon‐like peptide‐1 receptor agonist, liraglutide, in terms of key outcomes of
Publikováno v:
Diabetes Technology & Therapeutics. 22:892-903
Background: In silico trials in type 2 diabetes (T2D) would be useful for testing diabetes treatments and accelerating the development of new antidiabetic drugs. In this study, we present a T2D sim...
Autor:
ROBERTO VISENTIN, KATRINE BRODERSEN, BJØRN RICHELSEN, NIELS MOLLER, CHIARA DALLA MAN, MICHAEL F. NIELSEN
The early effects of bariatric surgery on insulin secretion and action in obese subjects with type 2 diabetes (T2D) remains poorly investigated. Here we assessed the mechanisms resulting in improved glucose intolerance using the oral minimal model ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e5a3e2e016117680a8ce52c7afc2fa4
https://hdl.handle.net/11577/3470857
https://hdl.handle.net/11577/3470857
Autor:
Roberto Visentin, Mattia De Lazzari
Publikováno v:
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. 2021
A type 2 diabetes (T2D) simulator has been recently proposed for supporting drug development and treatment optimization. This tool consists of a physiological model of glucose/insulin/C-peptide dynamics and a virtual cohort of T2D subjects (i.e., ran
Autor:
Chiara Dalla Man, Roberto Visentin, Jochen Sieber, Clemens Giegerich, Claudio Cobelli, Michele Schiavon, Thomas Klabunde
Publikováno v:
Diabetes Technology & Therapeutics
Background: Second-generation long-acting insulin glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) provide novel basal insulin therapies for the treatment of type 1 diabetes (T1D). Both offer a flatter pharmacokinetic (PK) profile than the
Autor:
Chiara Dalla Man, Claudio Cobelli, Roberto Visentin, Clemens Giegerich, Thomas Klabunde, Michele Schiavon
Publikováno v:
IEEE Transactions on Biomedical Engineering. 67:624-631
Objective: Subcutaneous (sc) administration of long-acting insulin analogs is often employed in multiple daily injection (MDI) therapy of type 1 diabetes (T1D) to cover patient's basal insulin needs. Among these, insulin glargine 100 U/mL (Gla-100) a